Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The only significant differences were found among participants with a 2 year age differences (57.5 vs. 59.3 years), that had had fewer previous fractures (22.6 vs 26.0 %), were taking less glucocorticoids (4.7 vs. 6.5 %) and had less osteoporosis according to baseline DXA scan (32.7 vs 37.3 %).FRIDEX cohort (Contacted/Non-Contacted)ContactedNon-Contacted p-value95 % CI1918 (56.5 %)1479 (43.5 %)Age (SD)57.5 (8.1)59.3 (9.9)0.001[1.1 to 2.4]BMI Kg/cm2 (SD)27.7 (4.6)27.5 (4.5)0.506nsBMI < 20 Kg/cm2 (%)2.42.60.723nsPersonal history of fractures (%)22.626.00.014[0.5 to 6.3]Parental Hip Fracture (%)22.721.10.335nsCurrent Smoking (%)10.810.80.802nsHigh alcohol intake (%)0.70.90.667nsGlucocorticoids (%)4.76.50.022[0.2 to 3.4]Rheumatoid arthritis (%)1.31.80.158nsCa + vitamin D supplements (%)22.222.20.916nsOsteoporosis in DXA (%)32.737.30.012[1.4 to 7.8] CI confidence interval, SD standard deviation, BMI body mass index, ns non statistical significance, DXA dual-energy X-ray absorptiometry

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Rationale of the Spanish FRAX model in decision-making for predicting osteoporotic fractures: an update of FRIDEX cohort of Spanish women

Study design awaiting verification · BMC Musculoskeletal Disorders · 2016

Original publication title

Rationale of the Spanish FRAX model in decision-making for predicting osteoporotic fractures: an update of FRIDEX cohort of Spanish women

Rafael Azagra; Marta Zwart; Gloria Encabo; Amada Aguyé; Juan Carlos Martin-Sánchez; Nuria Puchol-Ruiz; Paula Gabriel-Escoda; Sergio Ortiz-Alinque; Emilio Gené; Milagros Iglesias; David Moriña; Miguel Angel Diaz-Herrera; Mireia Utzet; Josep Maria Manresa; On behalf of GROIMAP study group

© The Author(s). 2016

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

The FRAX tool has been found to show a good discriminatory capacity for detecting women at high risk of fragility fracture, and is better for hip fracture than major fracture. The test of sensibility shows that it is, at least, not inferior than when using BMD model alone. The predictive capacity of FRAX tool needs some adjustment. This capacity is better for hip fracture prediction and better for women < 65 years. Further studies in Catalonia and other regions of Spain are needed to fine tune the FRAX tool’s predictive capability.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

The FRAX® tool estimates the risk of a fragility fracture among the population and many countries have been evaluating its performance among their populations since its creation in 2007.

The purpose of this study is to update the first FRIDEX cohort analysis comparing FRAX with the bone mineral density (BMD) model, and its predictive abilities.

Source: Background Source: Background

Abstract: What methods does the paper describe?

The discriminatory ability of the FRAX was assessed using the ‘area under curve’ of the receiver operating characteristic (AUC-ROC). Predictive ability was assessed by comparing estimated risk fractures with incidence fractures after a 10-year follow up period.

Source: Methods

Abstract: Results

One thousand three hundred eight women ≥ 40 and ≤ 90 years followed up during a 10-year period. The AUC for major osteoporotic fractures using FRAX without DXA was 0.686 (95 % CI 0.630 to 0.742) and using FN T-score of DXA 0.714 (95 % CI 0.661 to 0.767). Using only the traditional parameters of DXA (FN T-score), the AUC was 0.706 (95 % CI 0.652 to 0.760). The AUC for hip osteoporotic fracture was 0.883 (95 % CI 0.827 to 0.938), 0.857 (95 % CI 0.773 to 0.941), and 0.814 (95 % CI 0.712 to 0.916) respectively.

For major osteoporotic fractures, the overall predictive value using the ratio Observed fractures/Expected fractures calculated with FRAX without T-score of DXA was 2.29 and for hip fractures 2.28 and with the inclusion of the T-score 2.01 and 1.83 respectively. However, for hip fracture in women < 65 years was 1.53 and 1.24 respectively.

Source: Results

Abstract: Conclusions

The FRAX tool has been found to show a good discriminatory capacity for detecting women at high risk of fragility fracture, and is better for hip fracture than major fracture. The test of sensibility shows that it is, at least, not inferior than when using BMD model alone. The predictive capacity of FRAX tool needs some adjustment. This capacity is better for hip fracture prediction and better for women < 65 years. Further studies in Catalonia and other regions of Spain are needed to fine tune the FRAX tool’s predictive capability.

Source: Conclusions
Authors’ abstract

Background

The FRAX® tool estimates the risk of a fragility fracture among the population and many countries have been evaluating its performance among their populations since its creation in 2007.

The purpose of this study is to update the first FRIDEX cohort analysis comparing FRAX with the bone mineral density (BMD) model, and its predictive abilities.

Methods

The discriminatory ability of the FRAX was assessed using the ‘area under curve’ of the receiver operating characteristic (AUC-ROC). Predictive ability was assessed by comparing estimated risk fractures with incidence fractures after a 10-year follow up period.

Results

One thousand three hundred eight women ≥ 40 and ≤ 90 years followed up during a 10-year period. The AUC for major osteoporotic fractures using FRAX without DXA was 0.686 (95 % CI 0.630 to 0.742) and using FN T-score of DXA 0.714 (95 % CI 0.661 to 0.767). Using only the traditional parameters of DXA (FN T-score), the AUC was 0.706 (95 % CI 0.652 to 0.760). The AUC for hip osteoporotic fracture was 0.883 (95 % CI 0.827 to 0.938), 0.857 (95 % CI 0.773 to 0.941), and 0.814 (95 % CI 0.712 to 0.916) respectively.

For major osteoporotic fractures, the overall predictive value using the ratio Observed fractures/Expected fractures calculated with FRAX without T-score of DXA was 2.29 and for hip fractures 2.28 and with the inclusion of the T-score 2.01 and 1.83 respectively. However, for hip fracture in women < 65 years was 1.53 and 1.24 respectively.

Conclusions

The FRAX tool has been found to show a good discriminatory capacity for detecting women at high risk of fragility fracture, and is better for hip fracture than major fracture. The test of sensibility shows that it is, at least, not inferior than when using BMD model alone. The predictive capacity of FRAX tool needs some adjustment. This capacity is better for hip fracture prediction and better for women < 65 years. Further studies in Catalonia and other regions of Spain are needed to fine tune the FRAX tool’s predictive capability.

Publication and source details

Original title: Rationale of the Spanish FRAX model in decision-making for predicting osteoporotic fractures: an update of FRIDEX cohort of Spanish women

Rafael Azagra; Marta Zwart; Gloria Encabo; Amada Aguyé; Juan Carlos Martin-Sánchez; Nuria Puchol-Ruiz; Paula Gabriel-Escoda; Sergio Ortiz-Alinque; Emilio Gené; Milagros Iglesias; David Moriña; Miguel Angel Diaz-Herrera; Mireia Utzet; Josep Maria Manresa; On behalf of GROIMAP study group

BMC Musculoskeletal Disorders · 2016

© The Author(s). 2016https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.http://dx.doi.org/10.13039/501100004587Instituto de Salud Carlos IIIPI09/90507Azagra Rafael

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T20:04:02.668564+00:00

DOI: 10.1186/s12891-016-1096-6 · PMC4912785